Literature DB >> 25487351

Osteoblast-specific expression of the fibrous dysplasia (FD)-causing mutation Gsα(R201C) produces a high bone mass phenotype but does not reproduce FD in the mouse.

Cristina Remoli1, Stefano Michienzi1, Benedetto Sacchetti1, Alberto Di Consiglio1, Stefania Cersosimo1, Emanuela Spica1, Pamela G Robey2, Kenn Holmbeck2, Ana Cumano3, Alan Boyde4, Graham Davis4, Isabella Saggio5, Mara Riminucci1, Paolo Bianco1.   

Abstract

We recently reported the generation and initial characterization of the first direct model of human fibrous dysplasia (FD; OMIM #174800), obtained through the constitutive systemic expression of one of the disease-causing mutations, Gsα(R201C) , in the mouse. To define the specific pathogenetic role(s) of individual cell types within the stromal/osteogenic system in FD, we generated mice expressing Gsα(R201C) selectively in mature osteoblasts using the 2.3kb Col1a1 promoter. We show here that this results in a striking high bone mass phenotype but not in a mimicry of human FD. The high bone mass phenotype involves specifically a deforming excess of cortical bone and prolonged and ectopic cortical bone remodeling. Expression of genes characteristic of late stages of bone cell differentiation/maturation is profoundly altered as a result of expression of Gsα(R201C) in osteoblasts, and expression of the Wnt inhibitor Sost is reduced. Although high bone mass is, in fact, a feature of some types/stages of FD lesions in humans, it is marrow fibrosis, localized loss of adipocytes and hematopoietic tissue, osteomalacia, and osteolytic changes that together represent the characteristic pathological profile of FD, as well as the sources of specific morbidity. None of these features are reproduced in mice with osteoblast-specific expression of Gsα(R201C) . We further show that hematopoietic progenitor/stem cells, as well as more mature cell compartments, and adipocyte development are normal in these mice. These data demonstrate that effects of Gsα mutations underpinning FD-defining tissue changes and morbidity do not reflect the effects of the mutations on osteoblasts proper.
© 2014 American Society for Bone and Mineral Research.

Entities:  

Keywords:  BONE MARROW; FIBROUS DYSPLASIA; GNAS; GSα; HEMATOPOIETIC NICHE; MOUSE MODELS; OSTEOBLASTS

Mesh:

Substances:

Year:  2015        PMID: 25487351      PMCID: PMC5526456          DOI: 10.1002/jbmr.2425

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  63 in total

1.  The mineralization density of iliac crest bone from children with osteogenesis imperfecta.

Authors:  A Boyde; R Travers; F H Glorieux; S J Jones
Journal:  Calcif Tissue Int       Date:  1999-03       Impact factor: 4.333

2.  The hypothalamic control of bone mass, implication for the treatment of osteoporosis.

Authors:  G Karsenty; P Ducy
Journal:  Ann Endocrinol (Paris)       Date:  2006-04       Impact factor: 2.478

Review 3.  Stromal stem cells: marrow-derived osteogenic precursors.

Authors:  M Owen; A J Friedenstein
Journal:  Ciba Found Symp       Date:  1988

4.  Leptin regulates bone formation via the sympathetic nervous system.

Authors:  Shu Takeda; Florent Elefteriou; Regis Levasseur; Xiuyun Liu; Liping Zhao; Keith L Parker; Dawna Armstrong; Patricia Ducy; Gerard Karsenty
Journal:  Cell       Date:  2002-11-01       Impact factor: 41.582

5.  Downregulation of SOST/sclerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes.

Authors:  T Bellido
Journal:  J Musculoskelet Neuronal Interact       Date:  2006 Oct-Dec       Impact factor: 2.041

6.  Ligand-mediated activation of an engineered gs g protein-coupled receptor in osteoblasts increases trabecular bone formation.

Authors:  Edward C Hsiao; Susan M Millard; Alyssa Louie; Yong Huang; Bruce R Conklin; Robert A Nissenson
Journal:  Mol Endocrinol       Date:  2010-02-11

7.  Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsalpha-mutated skeletal progenitor cells.

Authors:  P Bianco; S A Kuznetsov; M Riminucci; L W Fisher; A M Spiegel; P G Robey
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

8.  The interplay of osteogenesis and hematopoiesis: expression of a constitutively active PTH/PTHrP receptor in osteogenic cells perturbs the establishment of hematopoiesis in bone and of skeletal stem cells in the bone marrow.

Authors:  Sergei A Kuznetsov; Mara Riminucci; Navid Ziran; Takeo W Tsutsui; Alessandro Corsi; Laura Calvi; Henry M Kronenberg; Ernestina Schipani; Pamela Gehron Robey; Paolo Bianco
Journal:  J Cell Biol       Date:  2004-12-20       Impact factor: 10.539

9.  Control of bone mass and remodeling by PTH receptor signaling in osteocytes.

Authors:  Charles A O'Brien; Lilian I Plotkin; Carlo Galli; Joseph J Goellner; Arancha R Gortazar; Matthew R Allen; Alexander G Robling; Mary Bouxsein; Ernestina Schipani; Charles H Turner; Robert L Jilka; Robert S Weinstein; Stavros C Manolagas; Teresita Bellido
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240

10.  Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment.

Authors:  Olaia Naveiras; Valentina Nardi; Pamela L Wenzel; Peter V Hauschka; Frederic Fahey; George Q Daley
Journal:  Nature       Date:  2009-06-10       Impact factor: 49.962

View more
  12 in total

Review 1.  Fibrous dysplasia of bone: craniofacial and dental implications.

Authors:  A B Burke; M T Collins; A M Boyce
Journal:  Oral Dis       Date:  2016-09-01       Impact factor: 3.511

2.  GsαR201C and estrogen reveal different subsets of bone marrow adiponectin expressing osteogenic cells.

Authors:  Biagio Palmisano; Rossella Labella; Samantha Donsante; Cristina Remoli; Emanuela Spica; Ilenia Coletta; Giorgia Farinacci; Michele Dello Spedale Venti; Isabella Saggio; Marta Serafini; Pamela Gehron Robey; Alessandro Corsi; Mara Riminucci
Journal:  Bone Res       Date:  2022-07-19       Impact factor: 13.362

3.  Induced GnasR201H expression from the endogenous Gnas locus causes fibrous dysplasia by up-regulating Wnt/β-catenin signaling.

Authors:  Sanjoy Kumar Khan; Prem Swaroop Yadav; Gene Elliott; Dorothy Zhang Hu; Ruoshi Xu; Yingzi Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-20       Impact factor: 11.205

Review 4.  [The activating GNAS mutation : A survey of fibrous dysplasia, its associated syndromes, and other skeletal and extraskeletal lesions].

Authors:  H Ostertag; S Glombitza
Journal:  Pathologe       Date:  2018-03       Impact factor: 1.011

5.  Constitutive stimulatory G protein activity in limb mesenchyme impairs bone growth.

Authors:  Anara Karaca; Vijayram Reddy Malladi; Yan Zhu; Olta Tafaj; Elena Paltrinieri; Joy Y Wu; Qing He; Murat Bastepe
Journal:  Bone       Date:  2018-02-20       Impact factor: 4.398

6.  p53-Sensitive Epileptic Behavior and Inflammation in Ft1 Hypomorphic Mice.

Authors:  Romina Burla; Mattia La Torre; Giorgia Zanetti; Alex Bastianelli; Chiara Merigliano; Simona Del Giudice; Alessandro Vercelli; Ferdinando Di Cunto; Marina Boido; Fiammetta Vernì; Isabella Saggio
Journal:  Front Genet       Date:  2018-11-27       Impact factor: 4.599

Review 7.  Advances in Models of Fibrous Dysplasia/McCune-Albright Syndrome.

Authors:  Hsuan Lung; Edward C Hsiao; Kelly L Wentworth
Journal:  Front Endocrinol (Lausanne)       Date:  2020-01-24       Impact factor: 5.555

Review 8.  The role of GPCRs in bone diseases and dysfunctions.

Authors:  Jian Luo; Peng Sun; Stefan Siwko; Mingyao Liu; Jianru Xiao
Journal:  Bone Res       Date:  2019-07-08       Impact factor: 13.567

Review 9.  Interplay of the nuclear envelope with chromatin in physiology and pathology.

Authors:  Romina Burla; Mattia La Torre; Klizia Maccaroni; Fiammetta Verni; Simona Giunta; Isabella Saggio
Journal:  Nucleus       Date:  2020-12       Impact factor: 4.197

Review 10.  Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation.

Authors:  Alison M Boyce; Michael T Collins
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.